Discounted Cash Flow
Corcept Therapeutics Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $8.1m | $18.2m | — | $0.07 |
| 2017 | — | $129.1m (1486.3%) | $60.5m (232.6%) | — | $1.14 (1528.6%) |
| 2018 | $251.2m | $75.4m (-41.6%) | $115.4m (90.6%) | 30.0% | $0.65 (-43.0%) |
| 2019 | $306.5m (22.0%) | $94.2m (24.9%) | $135.0m (17.0%) | 30.7% (2.4%) | $0.82 (26.2%) |
| 2020 | $353.9m (15.5%) | $106.0m (12.6%) | $150.7m (11.6%) | 30.0% (-2.5%) | $0.92 (12.2%) |
| 2021 | $366.0m (3.4%) | $112.5m (6.1%) | $167.4m (11.1%) | 30.7% (2.6%) | $0.97 (5.4%) |
| 2022 | $401.9m (9.8%) | $101.4m (-9.9%) | $119.9m (-28.4%) | 25.2% (-17.9%) | $0.95 (-2.1%) |
| 2023 | $482.4m (20.0%) | $106.1m (4.7%) | $126.9m (5.8%) | 22.0% (-12.8%) | $1.02 (7.4%) |
| 2024 | $675.0m (39.9%) | $141.2m (33.0%) | $195.9m (54.4%) | 20.9% (-4.9%) | $1.35 (32.4%) |
| 2025 | $761.4m (12.8%) | $99.7m (-29.4%) | $141.8m (-27.6%) | 13.1% (-37.4%) | $0.95 (-29.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.